Angiotensin converting enzyme inhibition does not affect response to exogenous angiotensin II in the forearm of mild-moderate hypertensive patients

What Was Tested

Researchers studied Angiotensin II in this randomized controlled trial publication.

It has been proposed that the suppression of endogenous levels of angiotensin II by angiotensin converting enzyme inhibition, may result in up-regulation of vascular AT1 receptors.

This study evaluated the effects of orally administered enalapril on angiotensin II induced vasoconstriction in the human forearm of patients with mild-moderate hypertension.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

A time span of 2 weeks appears in the methods.

What Was Measured

It has been proposed that the suppression of endogenous levels of angiotensin II by angiotensin converting enzyme inhibition, may result in up-regulation of vascular AT1 receptors.

This study evaluated the effects of orally administered enalapril on angiotensin II induced vasoconstriction in the human forearm of patients with mild-moderate hypertension.

The subject headings attached to it are Angiotensin II, Blood Flow Velocity, Blood Pressure, Enalapril, Forearm, Hypertension and Receptors, Angiotensin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II over 2 weeks.

The publication is from 1994 (European journal of clinical pharmacology), a journal based in Germany.

More context: the Angiotensin II compound page, all human trials.